These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8128833)

  • 1. Pharmacokinetic studies of cholinesterase inhibitors.
    Johansson M; Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():22-5. PubMed ID: 8128833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
    Crismon ML
    Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients.
    Johansson M; Hellström-Lindahl E; Nordberg A
    Dementia; 1996; 7(2):111-7. PubMed ID: 8866685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
    Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
    Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
    Håkansson L
    Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinesterasic drugs: tacrine but not physostigmine, accumulates in acidic compartments of the cells.
    Dell'Antone P; Bragadin M; Zatta P
    Biochim Biophys Acta; 1995 Apr; 1270(2-3):137-41. PubMed ID: 7727536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
    Grothe DR; Piscitelli SC; Dukoff R; Fullerton T; Sunderland T; Molchan SE
    J Clin Psychopharmacol; 1998 Feb; 18(1):78-81. PubMed ID: 9472847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroprotective therapy of Alzheimer's disease?].
    Mielke R
    Dtsch Med Wochenschr; 1996 Nov; 121(48):1515. PubMed ID: 8983909
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of drugs for Alzheimer's disease.
    Parnetti L
    Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
    Goh CW; Aw CC; Lee JH; Chen CP; Browne ER
    Drug Metab Dispos; 2011 Mar; 39(3):402-11. PubMed ID: 21148081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
    Ebmeier KP; Hunter R; Curran SM; Dougal NJ; Murray CL; Wyper DJ; Patterson J; Hanson MT; Siegfried K; Goodwin GM
    Psychopharmacology (Berl); 1992; 108(1-2):103-9. PubMed ID: 1410128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and early clinical studies with velnacrine.
    Siegfried KR
    Acta Neurol Scand Suppl; 1993; 149():26-8. PubMed ID: 8128834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of velnacrine, tacrine and physostigmine on tetanic twitch responses at the rat neuromuscular junction.
    Bosch F; Morales M; Badia A; Baños JE
    Eur J Pharmacol; 1992 Nov; 222(1):163-6. PubMed ID: 1468493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.